Facebook Linkedin RSS Twitter Youtube
Home 2023

Daiichi Sankyo

Merck, Daiichi Sankyo Ink Up-to-$22B Cancer ADC Collaboration
Cancer

Merck, Daiichi Sankyo Ink Up-to-$22B Cancer ADC Collaboration

Top 25 Biotech Companies of 2023
A-Lists

Top 25 Biotech Companies of 2023

You Can See Manhattan from Your Lab: $3B “Cove” Campus Announced in Jersey City
Drug Discovery

You Can See Manhattan from Your Lab: $3B “Cove” Campus Announced in Jersey City

AstraZeneca, Daiichi Sankyo Target TROP2 in Up-to-$6B Cancer Collaboration
Cancer

AstraZeneca, Daiichi Sankyo Target TROP2 in Up-to-$6B Cancer Collaboration

AstraZeneca, Daiichi Sankyo Launch Potentially $6.9B+ Collaboration to Develop Cancer ADC
Cancer

AstraZeneca, Daiichi Sankyo Launch Potentially $6.9B+ Collaboration to Develop Cancer ADC

Daiichi Sankyo Triples Down on Immuno-Oncology Collaboration with Zymeworks
Drug Discovery

Daiichi Sankyo Triples Down on Immuno-Oncology Collaboration with Zymeworks

MD Anderson, Daiichi Sankyo Partner to Develop AML Treatments
Cancer

MD Anderson, Daiichi Sankyo Partner to Develop AML Treatments

Daiichi Sankyo Returns U.S. Rights for Pain Candidate to Charleston Labs
Drug Discovery

Daiichi Sankyo Returns U.S. Rights for Pain Candidate to Charleston Labs

Daiichi Sankyo, Max Planck Innovation, Lead Discovery Center Launch Cancer Collaboration
Cancer

Daiichi Sankyo, Max Planck Innovation, Lead Discovery Center Launch Cancer Collaboration

Daiichi Sankyo Ends Biosimilar Enbrel Partnership with Coherus in Japan
Drug Discovery

Daiichi Sankyo Ends Biosimilar Enbrel Partnership with Coherus in Japan

123...5Page 1 of 5
Copyright © 2024 Genetic Engineering & Biotechnology News. All Rights Reserved.